MetaCap

Ernexa Therapeutics (ERNA) vs Purple Biotech (PPBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ernexa Therapeutics is the larger company by market cap ($2.3 million vs $1.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ERNA-43.10%PPBT+4.45%
+20%-13%-46%
Oct 7, 20261 yearNov 20, 2026
ERNA-43.33%PPBT+14.66%
+26%-10%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ERNA versus PPBT key metrics
MetricERNAPPBT
Share price$1.36$1.53
Market cap$2.30M$1.86M
1-day change-16.56%-4.09%
EPS (TTM)$-11.22$-47.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-14.08M$-26.39M
52-week high$37.50$8.90
52-week low$1.35$0.91
Distance from 52-week high-96.37%-82.87%
Analyst consensusnonenone
Avg. price target upside+2105.88%+1014.75%
Average volume43.90K1.26M
Shares outstanding1.69M1.22M
Employees510
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ernexa Therapeutics

ERNA stock →

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

ERNA vs PPBT FAQ

Which is bigger, Ernexa Therapeutics or Purple Biotech?

Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $2.30M compared with $1.86M for Purple Biotech (PPBT).

Are Ernexa Therapeutics and Purple Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons